SCHEMBL7808907

SCHEMBL7808907

[c]1oc2ccccc2c1-c1nccc2ccccc12

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.42
NPC1 O15118 4/20 0.42
RAB9A P51151 4/20 0.42
L3MBTL1 Q9Y468 2/20 0.42
GPR55 Q9Y2T6 1/20 0.42
MAPT P10636 5/20 0.42
KMT2A Q03164 2/20 0.42
GLA P06280 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
PLAU P00749 2/20 0.41
CYP2A6 P11509 1/20 0.41
F12 P00748 1/20 0.41
NCF1 P14598 1/20 0.41
NOS3 P29474 1/20 0.41
NOS1 P29475 1/20 0.41
NOS2 P35228 1/20 0.41
BACE1 P56817 1/20 0.41
ALDH1A1 P00352 3/20 0.37
HPGD P15428 2/20 0.37
HSD17B10 Q99714 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7474495 0.75 AR (0.39) KDM4ENPC1RAB9AL3MBTL1GPR55
SCHEMBL244548 0.75 NOS3 (0.41) NOS3NOS1NOS2
SCHEMBL199273 0.74 PLAU (0.60) KDM4ENPC1RAB9AL3MBTL1GPR55
SCHEMBL29923403 0.74 PLAU (0.60) KDM4ENPC1RAB9AL3MBTL1GPR55
SCHEMBL5567669 0.74 KDM4E (0.36) KDM4ENPC1RAB9AMAPTKMT2A
SCHEMBL6256201 0.73 MAPT (0.44) KDM4ENPC1RAB9AL3MBTL1MAPT
SCHEMBL30522769 0.72 PLAU (0.58) KDM4ENPC1RAB9AL3MBTL1GPR55
SCHEMBL3028469 0.72 BRD4 (0.40) KDM4EMAPTKMT2AALDH1A1HPGD
SCHEMBL646759 0.71 KDM4E (0.45) KDM4ENPC1RAB9AL3MBTL1MAPT
SCHEMBL12223316 0.70 PLAU (0.56) KDM4ENPC1RAB9AL3MBTL1GPR55

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10155725-B2 Anthelmintic compounds and compositions and method of using thereof MERIAL, INC. (US) 2018-12-18 US claimed
US-20010044461-A1 Novel N-aminoalkyldibenzothiopencarboxamide receptor subtype specific ligands YUAN JUN (US) 2001-11-22 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10155725-B2 Anthelmintic compounds and compositions and method of using thereof CYP3A5, ABCC5, CXXC5 KDM4E 326/4885NPC1 2184/4885RAB9A 3493/4885
US-20010044461-A1 Novel N-aminoalkyldibenzothiopencarboxamide receptor subtype specific ligands CNR1, GLRA1, SIGMAR1 KDM4E 4589/4885NPC1 862/4885RAB9A 2100/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.